FDA approves Eli Lilly weight loss pill

The FDA has approved a new GLP-1 weight loss medication from Eli Lilly, expanding the class of drugs that have become central to obesity treatment in recent years. GLP-1 drugs work by mimicking a hormone that regulates appetite and blood sugar, and Eli Lilly's approval adds competition to the market dominated by Novo Nordisk's Ozempic and Wegovy. The approval matters because it increases patient access to these in-demand medications and could intensify price competition in a rapidly growing market. Eli Lilly has already established itself as a major player in the space with tirzepatide, a dual-action drug that targets both GLP-1 and another hormone receptor. This latest approval underscores the pharmaceutical industry's focus on metabolic and weight management drugs, which have become some of the most sought-after treatments in medicine.